United States set
Menu Shopping cart $0 Search
Manufactured by BioVendor

Human soluble uPAR ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Soluble Plasminogen Aactivator Urokinase Receptor, Soluble Urokinase-Type Plasminogen Activator Receptor, Soluble uPAR, sPLAUR
  • Species:Human
Cat. No. Size Price

New REH001R 96 wells (1 kit) $518,5
PubMed Product Details
Technical Data


Sandwich ELISA, Biotin-labelled antibody


Serum, Plasma, Cell culture supernatant


On blue ice packs. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2–8°C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Range

16.38 - 4000 pg/ml

Limit of Detection

15 pg/ml

Intra-assay (Within-Run)

CV < 10%

Inter-assay (Run-to-Run)

CV < 12%

Spiking Recovery

serum 111.2%, plasma 103,2%, cell culture media 101.2%

Dilution Linearity

serum 113.3%, plasma 118,9%, cell culture media 122.1%


This ELISA kit shows no cross-reactivity with the following cytokines tested: human Angiogenin, BDNF, BLC, CNTF, ENA-78, FGF-4, IL-1 alpha, IL-1 beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12 p70, IL-12 p40, IL-13, IL-15, I-309, IP-10, FGF-4, FGF-6, FGF-7, G-CSF, GDNF, GM-CSF, IFN-gamma, IGFBP-2, IGFBP-3, IGFBP-4, Leptin (OB), MCP-1, MCP-2, MCP-3, MDC, MIF, MIG, MIP-1 alpha, MIP-1 beta, MIP-1 delta, PARC, PDGF, RANTES, SCF, SDF-1 alpha, TARC, TGF-alpha, TIMP-1, TIMP-2, TNF-alpha, TNFbeta, TPO, VEGF.



  • RUO
  • calibration range 16.38 - 4 000 pg/ml
  • limit of detection 15 pg/ml
  • intra-assay CV <10%
  • inter-assay CV < 12%

Research topic

Immune Response, Infection and Inflammation, Renal disease


BioVendor Human soluble uPAR (urokinase-type plasminogen activator receptor, uPAR: suPAR, soluble plasminogen activator urokinase receptor, soluble urokinase-type plasminogen activator receptor, PLAUR, sPLAUR) ELISA kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of human suPAR in serum, plasma, and cell culture supernatants. The assay employs an antibody specific for human suPAR coated on a 96-well plate. Standards and samples are pipetted into the wells and suPAR present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-human suPAR antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of suPAR bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.

Summary References (15)

References to suPAR

  • Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. J Med Virol. 2008 Feb;80 (2):209-16
  • Donadello K, Scolletta S, Covajes C, Vincent JL. suPAR as a prognostic biomarker in sepsis. BMC Med. 2012;10:2
  • Fernebro E, Madsen RR, Ferno M, Brunner N, Bendahl P, Christensen IJ, Johnson A, Nilbert M. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients. Eur J Cancer. 2001 Mar;37 (4):486-91
  • Fidan E, Mentese A, Ozdemir F, Deger O, Kavgaci H, Caner Karahan S, Aydin F. Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer. Med Oncol. 2013 Jun;30 (2):540
  • Haugaard SB, Andersen O, Hansen TW, Eugen-Olsen J, Linneberg A, Madsbad S, Olsen MH, Jorgensen T, Borch-Johnsen K, Jeppesen J. The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men. Diabet Med. 2012 Apr;29 (4):479-87
  • Heraclides A, Jensen TM, Rasmussen SS, Eugen-Olsen J, Haugaard SB, Borch-Johnsen K, Sandbaek A, Lauritzen T, Witte DR. The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status. Diabetologia. 2013 Jul;56 (7):1542-6
  • Huttunen R, Syrjanen J, Vuento R, Hurme M, Huhtala H, Laine J, Pessi T, Aittoniemi J. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med. 2011 Jul;270 (1):32-40
  • Jalkanen V, Yang R, Linko R, Huhtala H, Okkonen M, Varpula T, Pettila V, Tenhunen J. SuPAR and PAI-1 in critically ill, mechanically ventilated patients. Intensive Care Med. 2013 Mar;39 (3):489-96
  • Koch A, Tacke F. Risk stratification and triage in the emergency department: has this become 'suPAR' easy?. J Intern Med. 2012 Sep;272 (3):243-6
  • Maas RJ, Deegens JK, Wetzels JF. Serum suPAR in patients with FSGS: trash or treasure?. Pediatr Nephrol. 2013 Jul;28 (7):1041-8
  • Persson M, Engstrom G, Bjorkbacka H, Hedblad B. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmo Diet and Cancer Study. Atherosclerosis. 2012 Feb;220 (2):502-5
  • Tzanakaki G, Paparoupa M, Kyprianou M, Barbouni A, Eugen-Olsen J, Kourea-Kremastinou J. Elevated soluble urokinase receptor values in CSF, age and bacterial meningitis infection are independent and additive risk factors of fatal outcome. Eur J Clin Microbiol Infect Di. 2012 Jun;31 (6):1157-62
  • Uusitalo-Seppala R, Huttunen R, Tarkka M, Aittoniemi J, Koskinen P, Leino A, Vahlberg T, Rintala EM. Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study. J Intern Med. 2012 Sep;272 (3):247-56
  • Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011 Aug;17 (8):952-60
  • Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, McMahan JL, Radeva M, Heil KM, Trautmann A, Anarat A, Emre S, Ghiggeri GM, Ozaltin F, Haffner D, Gipson DS, Kaskel F, Fischer DC, Schaefer F, Reiser J. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol. 2012 Dec;23 (12):2051-9
Related Products Docs